VTCN1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P10713(VTCN1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10713(VTCN1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

VTCN1 (B7-H4) is a transmembrane protein belonging to the B7 family of immune checkpoint regulators, primarily involved in modulating T-cell-mediated immune responses. Expressed on antigen-presenting cells and certain non-hematopoietic tissues, VTCN1 interacts with an unknown receptor on T cells to suppress their activation, proliferation, and cytokine production. This inhibitory mechanism helps maintain immune tolerance but is frequently exploited by tumors to evade immune surveillance. Overexpression of VTCN1 has been documented in various cancers, including breast, ovarian, and pancreatic malignancies, correlating with poor prognosis and resistance to therapies.

Antibodies targeting VTCN1 aim to block its immunosuppressive signaling, thereby restoring antitumor immunity. Preclinical studies demonstrate that anti-VTCN1 antibodies enhance T-cell activity and synergize with PD-1/PD-L1 inhibitors. However, challenges remain, such as identifying optimal therapeutic contexts and managing potential autoimmune side effects due to VTCN1’s expression in healthy tissues. Several anti-VTCN1 agents, including monoclonal antibodies and antibody-drug conjugates, are under investigation in early-phase clinical trials. Research continues to explore its dual role as a diagnostic biomarker and therapeutic target, highlighting its potential in precision immuno-oncology strategies.